▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Korea’s botulinum toxin maker Hugel said on Feb. 1 that it has completed the merger with its two wholly owned subsidiaries Hugel Pharma and Hugel Meditec. “The merge aims at strength...
[THE INVESTOR] Korea’s biotech firm Pharmabcine said on Jan. 31 that it has entered a partnership agreement with MSD to evaluate its human monoclonal antibody TTAC-0001 in combination with MSD’s ant...
[THE INVESTOR] Samsung BioLogics posted an operating income last year, shifting from a loss a year earlier, the company said on Jan. 31. The total reached 63 billion won (US$60 million) in 2017,...
[THE INVESTOR] HanAll Biopharma, a subsidiary of Daewoong Pharmaceutical, is negotiating with a Japanese company for a possible licensing deal to grant exclusive rights to its anti-FcRn monoclonal a...
[THE INVESTOR] Amorepacific said on Jan. 31 its fourth-quarter net profit dropped 76.2 percent from the previous year, due largely to a sharp decline in the number of Chinese tourists. Net incom...
[THE INVESTOR] Korea’s biotech firm Genexine is gearing up to find the right partner to jointly develop its long-acting drug for growth hormone deficiency currently in mid-stage clinical trials to t...
[THE INVESTOR] Samsung Bioepis, a joint venture between Samsung BioLogics and Biogen, is likely to swing to black in 2018 as its biosimilar products start to bear fruits, according to a local securi...
[THE INVESTOR] Daewoong Pharmaceuticals said on Jan. 29 that it has signed two contracts worth a combined US$21 million to take its botulinum toxin product Nabota to markets in Brazil and Egypt. Da...
[THE INVESTOR] Korean drug maker Bukwang Pharma said on Jan. 29 that it expects to complete phase 2b clinical trials of its drug candidate for type 2 diabetes by the end of this year. The potential...
[THE INVESTOR] Stock values for stakeowners of pharmaceutical and biotech firms nearly doubled over the past year, industry data showed on Jan. 28. A total of 32 people each owned more than 100 bil...
[THE INVESTOR] SK Biotek, the pharmaceutical unit of energy and telecom conglomerate SK Group, said on Jan. 26 it has held an opening ceremony for its plant in Ireland, the latest attempt to expand ...
[THE INVESTOR] The European sales of Samsung Bioepis’ first biosimilar Benepali, its copycat version of Amgen’s anti-inflammatory Enbrel, increased nearly threefold in 2017, according to the earning...
[THE INVESTOR] A potential gene therapy under development by Korean biotech firm ViroMed could be worth over 10 trillion won (US$9.33 billion), according to a local securities firm on Jan. 24. Vi...
[THE INVESTOR] Korean drug developer Enzychem Lifesciences ’ upcoming relisting on KOSDAQ is getting strong demand from investors, with the target price range more than doubling in a week, accordi...
[THE INVESTOR] Korea’s biotech firm PharmAbcine said on Jan. 23 it has completed a pre-Investigational New Drug meeting with the US Food and Drug Administration for its lead candidate TTAC0001, pa...
Why birth order is a big deal at LG
JB Financial’s Phnom Penh Commercial Bank expands on upbeat earnings
Line becomes largest shareholder of Taiwan’s iPass
Kakao sets up holding firm to control blockchain units
Park Hyeon-joo steps down as Mirae Asset Daewoo chairman
Esmo denies merger talks with Samsung
Prosecutors raid Samsung Electronics
‘Nut rage’ Korean Air’s Cho Hyun-ah banned from leaving country
May 25, 2018
